CN101965396B - 具有丙型肝炎病毒基因的重组痘苗病毒 - Google Patents

具有丙型肝炎病毒基因的重组痘苗病毒 Download PDF

Info

Publication number
CN101965396B
CN101965396B CN200980107538XA CN200980107538A CN101965396B CN 101965396 B CN101965396 B CN 101965396B CN 200980107538X A CN200980107538X A CN 200980107538XA CN 200980107538 A CN200980107538 A CN 200980107538A CN 101965396 B CN101965396 B CN 101965396B
Authority
CN
China
Prior art keywords
dna
hcv
virus
base sequence
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980107538XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101965396A (zh
Inventor
小原道法
村井深
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Km Biomedical Co Ltd
Tokyo Metropolitan Institute of Medical Science
Original Assignee
Common financial group legal person chemical and serum therapy research institute
Tokyo Metropolitan Institute of Medical Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Common financial group legal person chemical and serum therapy research institute, Tokyo Metropolitan Institute of Medical Science filed Critical Common financial group legal person chemical and serum therapy research institute
Publication of CN101965396A publication Critical patent/CN101965396A/zh
Application granted granted Critical
Publication of CN101965396B publication Critical patent/CN101965396B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/203—Animal model comprising inducible/conditional expression system, e.g. hormones, tet
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200980107538XA 2008-03-07 2009-03-06 具有丙型肝炎病毒基因的重组痘苗病毒 Expired - Fee Related CN101965396B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008057515 2008-03-07
JP2008-057515 2008-03-07
JP2008294361A JP5584407B2 (ja) 2008-03-07 2008-11-18 Ｃ型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス
JP2008-294361 2008-11-18
PCT/JP2009/054825 WO2009110644A1 (ja) 2008-03-07 2009-03-06 C型肝炎ウイルス遺伝子を有する組換えワクシニアウイルス

Publications (2)

Publication Number Publication Date
CN101965396A CN101965396A (zh) 2011-02-02
CN101965396B true CN101965396B (zh) 2013-08-14

Family

ID=41056188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980107538XA Expired - Fee Related CN101965396B (zh) 2008-03-07 2009-03-06 具有丙型肝炎病毒基因的重组痘苗病毒

Country Status (9)

Country Link
US (1) US9000136B2 (enExample)
EP (1) EP2267120B1 (enExample)
JP (1) JP5584407B2 (enExample)
KR (1) KR101607349B1 (enExample)
CN (1) CN101965396B (enExample)
AU (1) AU2009220401B2 (enExample)
CA (1) CA2717626A1 (enExample)
ES (1) ES2573704T3 (enExample)
WO (1) WO2009110644A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101913553B1 (ko) 2010-10-15 2018-11-05 고에키자이단호진 도쿄도 이가쿠 소고겐큐쇼 신형 인플루엔자 바이러스 유래 헤마글루티닌 단백질 유전자를 갖는 재조합 백시니아 바이러스
EP2950817B1 (en) * 2013-01-31 2019-08-07 Portland State University Immunogenic compositions comprising silicified virus and methods of use
WO2014162031A1 (es) * 2013-04-02 2014-10-09 Consejo Superior De Investigaciones Científicas (Csic) Vectores recombinantes basados en el virus modificado de ankara (mva) como vacunas preventivas y terapéuticas contra la hepatitis c
ES2869575T3 (es) * 2014-11-11 2021-10-25 Nobelpharma Co Ltd Composición farmacéutica para el tratamiento y/o la prevención de la hepatitis C

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942585A (zh) * 2004-02-20 2007-04-04 财团法人东京都医学研究机构 含人丙型肝炎病毒全长基因组的核酸构建物、核酸构建物转入其中的重组全长病毒基因组复制型细胞和生产丙型肝炎病毒颗粒的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06237773A (ja) 1992-12-22 1994-08-30 Tonen Corp ポックスウイルスのａ型封入体（ａｔｉ）プロモーター及び前期プロモーターを含んで成る外来遺伝子発現ベクター
JP2003064096A (ja) * 2001-08-29 2003-03-05 Mitsubishi Kagaku Bio-Clinical Laboratories Inc Ｃ型肝炎ウイルス特異的細胞障害性ｔ細胞認識エピトープ
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
FR2855758B1 (fr) * 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
EP1710300A4 (en) * 2003-12-05 2007-10-24 Hokkaido Tech Licensing Office HIGHLY SAFE POX VACCINE VIRUS AND VACCINIA VIRUS VECTOR
JPWO2006013815A1 (ja) * 2004-08-02 2008-05-01 財団法人ヒューマンサイエンス振興財団 ＨＣＶウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
JP4665122B2 (ja) * 2004-10-08 2011-04-06 財団法人 東京都医学研究機構 組み換えウイルスおよびその用途
JP2008057515A (ja) 2006-09-04 2008-03-13 Mitsubishi Heavy Ind Ltd ピックアップセンサの出力電圧判定方法および装置
JP5103058B2 (ja) 2007-05-28 2012-12-19 株式会社日立ハイテクノロジーズ 欠陥観察装置及び欠陥観察方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1942585A (zh) * 2004-02-20 2007-04-04 财团法人东京都医学研究机构 含人丙型肝炎病毒全长基因组的核酸构建物、核酸构建物转入其中的重组全长病毒基因组复制型细胞和生产丙型肝炎病毒颗粒的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AY045702;K.TSUKIYAMA-KOHARA;《NCBI》;20070905;1 *

Also Published As

Publication number Publication date
WO2009110644A1 (ja) 2009-09-11
AU2009220401A1 (en) 2009-09-11
AU2009220401B2 (en) 2015-07-30
EP2267120A4 (en) 2012-06-27
EP2267120A1 (en) 2010-12-29
US9000136B2 (en) 2015-04-07
CA2717626A1 (en) 2009-09-11
US20110275139A1 (en) 2011-11-10
ES2573704T3 (es) 2016-06-09
CN101965396A (zh) 2011-02-02
EP2267120B1 (en) 2016-05-18
KR101607349B1 (ko) 2016-03-29
KR20100131480A (ko) 2010-12-15
JP5584407B2 (ja) 2014-09-03
JP2009232836A (ja) 2009-10-15

Similar Documents

Publication Publication Date Title
CN106794239B (zh) 对抗肠病毒感染的基于腺病毒载体的疫苗
CN109182380B (zh) 杆状病毒表达的猪瘟e2亚单位疫苗的制备方法及应用
TW202203966A (zh) 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗
CN102210861A (zh) 丙型肝炎病毒多表位肽负荷的树突状细胞治疗性疫苗
CN101965396B (zh) 具有丙型肝炎病毒基因的重组痘苗病毒
CN103571798B (zh) 鸭坦布苏病毒弱毒株及其应用
EP3549604A1 (en) Recombinant bivalent inactivated vaccine for foot-and-mouth disease and preparation method and application thereof
JP6175167B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子を有する組換えワクシニアウイルス
CN101966341A (zh) 腺病毒/甲病毒复制子嵌合载体猪瘟疫苗及其应用
CN107206035B (zh) 丙型肝炎的治疗和/或预防用药物组合物
WO2024152974A1 (zh) 一种定向减毒的痘苗病毒疫苗
CN103757032A (zh) 一种以流感病毒为载体的hcv嵌合疫苗及其制备方法
CN113308440B (zh) 一种n7-甲基转移酶缺陷型冠状病毒减毒疫苗株及其制备方法与应用
Iyer et al. Complete genome analysis and virulence characteristics of the Louisiana West Nile virus strain LSU–AR01
CN109172818A (zh) 一种蛋白牛痘疫苗及其效力检测方法
WO2006013815A1 (ja) ＨＣＶウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用
Murayama et al. SPECIFIC RNA STRUCTURES AND MUTATIONS IMPLICATED FOR HCV RNA REPLICATION AND VIRUS PARTICLE FORMATION IN CULTURED CELLS: 1421
JP5944210B2 (ja) 新型インフルエンザウイルス由来ヘマグルチニンタンパク質遺伝子が組み込まれたｂ５ｒ遺伝子欠損組換えワクシニアウイルス
CN101663399A (zh) 一种抗hcv的疫苗及其制备方法和用途
CN117701636A (zh) 一种表达il-15超级激动剂的溶瘤病毒的构建方法与应用
CN120837685A (zh) 一种基于重组黑猩猩溶瘤腺病毒的药物组合物及其在结直肠癌治疗中的应用
CN104480123A (zh) 一种hcv包膜蛋白基因及应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Tokyo, Japan

Applicant after: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE

Co-applicant after: Common Financial Group Legal Person Chemical and Serum Therapy Research Institute

Address before: Tokyo, Japan

Applicant before: Tokyo Metropolitan Org Med Res

Co-applicant before: Common Financial Group Legal Person Chemical and Serum Therapy Research Institute

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: TOKYO METROPOLITAN ORGANIZATION FOR MEDICINE RESEARCH TO: TOKYO METROPOLITAN ORGANIZATION FOR MEDICAL RESEARCH

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20190307

Address after: Tokyo, Japan

Co-patentee after: KM Biomedical Co., Ltd.

Patentee after: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE

Address before: Tokyo, Japan

Co-patentee before: Common Financial Group Legal Person Chemical and Serum Therapy Research Institute

Patentee before: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130814

Termination date: 20210306

CF01 Termination of patent right due to non-payment of annual fee